ADVL1414, A Phase 1 Study of Selinexor (KPT-330), a Selective XP01 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Study of Selinexor in Pediatric Solid Tumors, including CNS Tumors
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAQ4204
U.S. Govt. ID: NCT02323880
Contact: Luca Szalontay, MD: 212-305-9770 / ls3399@cumc.columbia.edu
Additional Study Information: We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects selinexor can cause; To learn more about the pharmacology (how your body handles the drug) of selinexor; To learn more about the biology of selinexor in blood and tumor tissue; To determine whether selinexor is a beneficial treatment for your tumor.
This study is closed
Investigator
Nobuko Hijiya, MD
Do You Qualify?
Does your child have a solid tumor, including lymphoma and CNS tumors, or a glioma? Yes No
Is your child between 12 months to 21 years of age? Yes No
Has your child received a solid organ transplantation? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Luca Szalontay, MD
ls3399@cumc.columbia.edu
212-305-9770
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE